# Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer

> **NCT02594371** · PHASE3 · COMPLETED · sponsor: **Athenex, Inc.** · enrollment: 402 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Oraxol
- **DRUG:** IV paclitaxel

## Key facts

- **NCT ID:** NCT02594371
- **Lead sponsor:** Athenex, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-02
- **Primary completion:** 2019-07-25
- **Final completion:** 2022-06-30
- **Target enrollment:** 402 (ACTUAL)
- **Last updated:** 2022-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02594371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02594371, "Ph3 Study To Determine Safety,Tolerability&Tumor Response Of Oraxol Compared To Taxol In Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02594371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*